Skip to main content
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

  • Register
  • Log in
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in

Search

  • Advanced search
Cancer Research
Cancer Research

Advanced Search

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
Tumor Biology

Abstract #4810: The metastasis suppressor RhoGDI2 suppresses expression of Versican,
an invasion associated and macrophage stimulatory molecule

Neveen Said and Dan Theodorescu
Neveen Said
University of Virginia, Charlottesville, VA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dan Theodorescu
University of Virginia, Charlottesville, VA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI:  Published May 2009
  • Article
  • Info & Metrics
Loading
AACR Annual Meeting-- Apr 18-22, 2009; Denver, CO

Abstract

Nearly half of bladder cancer patients that present with locally advanced disease have occult distant metastases at presentation and poor 5-year survival rate. In human bladder cancer, reduction of Rho GDP Dissociation Inhibitor 2 (RhoGDI2) has been identified as an independent prognostic marker of tumor metastasis in patients with locally advanced disease and a lung metastasis suppressor gene in animal models of the disease. To determine how this protein affects metastasis, we transfected and stably expressed a RhoGDI2 transgene in the RhoGDI2 negative and metastatic UMUC3 human bladder cancer cell line and carried out expression profiling. The genes differentially expressed among the UMUC3-GFP (control) and UMUC3-RhoGDI2 cells were then evaluated against a panel of genes that were recently found to be associated with bladder cancer migration in vitro and invasion in patients (Wu Y et al, Oncogene. 2008, 27(52):6679). This analysis revealed that chondroitin sulfate proteoglycan 2 (CSPG2), versican, was downregulated by RhoGDI2 as well as positively correlated with bladder cancer stage and in vitro migration of bladder cancer cell lines. Confirmation of gene expression profiling by qPCR and western revealed that RhoGDI2 transfected UMUC3 cells had reduced expression and secretion of versican isoforms V1 and V2 as compared to vector control cells. Silencing versican expression in parental UMUC3 cells by small interfering RNA (siRNA) resulted in significant decrease in UMUC3 cell migration. Since versican has been shown to be a stimulator of macrophage activity which in turn is a promoter of the metastatic tumor growth, we evaluated the effect of versican depletion on bladder cancer macrophage cross talk in vitro. Versican siRNA in UMUC3 resulted in a ~60% inhibition of macrophage-induced UMUC3 cell migration, as well as ~50% decrease in UMUC3-induced macrophage chemotaxis. These effects were similar in magnitude to those observed with RhoGDI2 transfection in UMUC3 cells. Together these findings indicate that metastasis suppressor effect of RhoGDI2 may in part be mediated through downregulation of versican and subsequent attenuation of cancer cell-macrophage cross-talk.

Citation Information: In: Proc Am Assoc Cancer Res; 2009 Apr 18-22; Denver, CO. Philadelphia (PA): AACR; 2009. Abstract nr 4810.

Footnotes

  • 100th AACR Annual Meeting-- Apr 18-22, 2009; Denver, CO

  • American Association for Cancer Research
Back to top
Cancer Research: 69 (9 Supplement)
May 2009
Volume 69, Issue 9 Supplement
  • Table of Contents
  • Index by Author

Sign up for alerts

Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Abstract #4810: The metastasis suppressor RhoGDI2 suppresses expression of Versican,an invasion associated and macrophage stimulatory molecule
(Your Name) has forwarded a page to you from Cancer Research
(Your Name) thought you would be interested in this article in Cancer Research.
Citation Tools
Abstract #4810: The metastasis suppressor RhoGDI2 suppresses expression of Versican,
an invasion associated and macrophage stimulatory molecule
Neveen Said and Dan Theodorescu
Cancer Res May 1 2009 (69) (9 Supplement) 4810;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Abstract #4810: The metastasis suppressor RhoGDI2 suppresses expression of Versican,
an invasion associated and macrophage stimulatory molecule
Neveen Said and Dan Theodorescu
Cancer Res May 1 2009 (69) (9 Supplement) 4810;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
Advertisement

Related Articles

Cited By...

More in this TOC Section

Tumor Biology

  • Abstract SY34-04: Do we need to know what pO2 hypoxia is
  • Abstract SY28-04: Rational incorporation of novel agents into multimodality treatment of glioma and neuroblastoma
  • Abstract SY28-02: Connections in the BRCA1-BRCA2 pathway of homologous recombination: Implications for breast cancer development and treatment
Show more 3

Molecular Pathophysiology of the Metastasis Process -- Oral Presentations - Proffered Abstracts

  • Abstract #4813: Requirement of SIP90 for hedgehog signaling and pancreatic cancer metastasis
  • Abstract #4812: Exposure of colon carcinoma cells to hepatic microenvironment and of hepatic cells to tumor factors promotes gene expression mimic contributing to organ tropism and metastasis development
  • Abstract #4811: The organ environment determines differential metastasis related gene expression in prostate cancer cell lines LNCaP-LN3 and LNCaP-PRO5
Show more 3
  • Home
  • Alerts
  • Feedback
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians
  • Reviewers

About Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2018 by the American Association for Cancer Research.

Cancer Research Online ISSN: 1538-7445
Cancer Research Print ISSN: 0008-5472
Journal of Cancer Research ISSN: 0099-7013
American Journal of Cancer ISSN: 0099-7374

Advertisement